GCCL Announces COVID-19 Neutralizing Antibody Analysis Method... Capable of Analyzing up to BA.5

[Asia Economy Reporter Chunhee Lee] Clinical trial specimen analysis institution GCCL announced on the 25th that it will participate in the 2022 Korean Society for Virology Research Association Joint Regular Academic Conference held for two days from the 26th in Yangyang-gun, Gangwon Province, and present its latest research results in poster form.

The Korean Society for Virology Research Association Joint Regular Academic Conference is a regular academic conference involving a total of eight virus research associations, including the Respiratory Virus Research Association and the Hepatitis Virus Research Association.

GCCL's presentation is titled "Optimization and Evaluation of Focus Reduction Neutralization Test (FRNT) for SARS-CoV-2." GCCL optimized the FRNT neutralizing antibody analysis method for the wild-type and Delta variants of COVID-19, as well as for Omicron and its subvariant BA.5, using the standard serum from the National Institute for Biological Standards and Control (NIBSC) in the UK.

Heeju Lee, Head of Research Operations at GCCL, stated, "Through this study utilizing Biosafety Level 3 (BL3) facilities, it has become possible to analyze FRNT neutralizing antibodies against the novel COVID-19 variant Omicron BA.5 virus," adding, "This will be helpful for clinical research and development by COVID-19 vaccine and therapeutic developers in the future."